169 related articles for article (PubMed ID: 32722730)
1. Revisiting amantadine as a treatment for drug-induced movement disorders.
Caroff SN; Jain R; Morley JF
Ann Clin Psychiatry; 2020 Aug; 32(3):198-208. PubMed ID: 32722730
[TBL] [Abstract][Full Text] [Related]
2. Amantadine versus trihexyphenidyl in the treatment of neuroleptic-induced parkinsonism.
Fann WE; Lake CR
Am J Psychiatry; 1976 Aug; 133(8):940-3. PubMed ID: 782262
[TBL] [Abstract][Full Text] [Related]
3. Amantadine in the treatment of Parkinson's disease and other movement disorders.
Rascol O; Fabbri M; Poewe W
Lancet Neurol; 2021 Dec; 20(12):1048-1056. PubMed ID: 34678171
[TBL] [Abstract][Full Text] [Related]
4. Treating extrapyramidal reactions: some current issues.
Gelenberg AJ
J Clin Psychiatry; 1987 Sep; 48 Suppl():24-7. PubMed ID: 2887554
[TBL] [Abstract][Full Text] [Related]
5. [Experience with the use of midantan for treatment and prevention of the neuroleptic syndrome].
Kamianov IM; Kupisk AG; Katsen IZ
Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(8):1218-23. PubMed ID: 4149581
[No Abstract] [Full Text] [Related]
6. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients.
Spivak B; Mester R; Abesgaus J; Wittenberg N; Adlersberg S; Gonen N; Weizman A
J Clin Psychiatry; 1997 Jul; 58(7):318-22. PubMed ID: 9269253
[TBL] [Abstract][Full Text] [Related]
7. Development of tolerance to the therapeutic effect of amantadine on akathisia.
Zubenko GS; Barreira P; Lipinski JF
J Clin Psychopharmacol; 1984 Aug; 4(4):218-20. PubMed ID: 6470196
[TBL] [Abstract][Full Text] [Related]
8. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
Silver H; Geraisy N; Schwartz M
J Clin Psychiatry; 1995 Apr; 56(4):167-70. PubMed ID: 7713856
[TBL] [Abstract][Full Text] [Related]
9. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
Oertel W; Eggert K; Pahwa R; Tanner CM; Hauser RA; Trenkwalder C; Ehret R; Azulay JP; Isaacson S; Felt L; Stempien MJ
Mov Disord; 2017 Dec; 32(12):1701-1709. PubMed ID: 28833562
[TBL] [Abstract][Full Text] [Related]
10. Amantadine and other antiglutamate agents: management of Parkinson's disease.
Mov Disord; 2002; 17 Suppl 4():S13-22. PubMed ID: 12211136
[No Abstract] [Full Text] [Related]
11. Neuroleptic-induced catatonia after abrupt withdrawal of amantadine during neuroleptic therapy.
Brown CS; Wittkowsky AK; Bryant SG
Pharmacotherapy; 1986; 6(4):193-5. PubMed ID: 2877444
[TBL] [Abstract][Full Text] [Related]
12. Extended-Release Amantadine for Levodopa-Induced Dyskinesia.
Dashtipour K; Tafreshi AR; Pahwa R; Lyons KE
Expert Rev Neurother; 2019 Apr; 19(4):293-299. PubMed ID: 30892103
[TBL] [Abstract][Full Text] [Related]
13. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents--preclinical studies.
Danysz W; Parsons CG; Kornhuber J; Schmidt WJ; Quack G
Neurosci Biobehav Rev; 1997 Jul; 21(4):455-68. PubMed ID: 9195603
[TBL] [Abstract][Full Text] [Related]
14. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study.
Snow BJ; Macdonald L; Mcauley D; Wallis W
Clin Neuropharmacol; 2000; 23(2):82-5. PubMed ID: 10803797
[TBL] [Abstract][Full Text] [Related]
15. [Study of hemantane effects in rats on a model of early (premotor) stage of Parkinson's disease].
Nepoklonov AV; Kapitsa IG; Ivanova EA; Voronina TA; Val'dman EA
Eksp Klin Farmakol; 2012; 75(11):3-6. PubMed ID: 23323324
[TBL] [Abstract][Full Text] [Related]
16. A double-blind study of amantadine hydrochloride versus benztropine mesylate in drug-induced parkinsonism.
Kelly JT; Zimmermann RL; Abuzzahab FS; Schiele BC
Pharmacology; 1974; 12(2):65-73. PubMed ID: 4610599
[No Abstract] [Full Text] [Related]
17. Treatment of acute neuroleptic-induced movement disorders.
Tonda ME; Guthrie SK
Pharmacotherapy; 1994; 14(5):543-60. PubMed ID: 7997388
[TBL] [Abstract][Full Text] [Related]
18. Adverse effects of antipsychotic drugs.
Malhotra AK; Litman RE; Pickar D
Drug Saf; 1993 Dec; 9(6):429-36. PubMed ID: 7907481
[TBL] [Abstract][Full Text] [Related]
19. The effect of amantadine on neuroleptic-induced parkinsonism.
Rüther E; Fussmann-Hegewald M; Eben E
Act Nerv Super (Praha); 1973 May; 15(2):93. PubMed ID: 4148089
[No Abstract] [Full Text] [Related]
20. An Evidence-Based Update on Anticholinergic Use for Drug-Induced Movement Disorders.
Vanegas-Arroyave N; Caroff SN; Citrome L; Crasta J; McIntyre RS; Meyer JM; Patel A; Smith JM; Farahmand K; Manahan R; Lundt L; Cicero SA
CNS Drugs; 2024 Apr; 38(4):239-254. PubMed ID: 38502289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
